David T Curiel

This inventor holds 41 USPTO granted patents and 8 published patent applications and 3 EPO patents, primarily in Gene Therapy. Top assignees: The UAB Research Foundation (The University of Alabama at Birmingham), Boehringer Ingelheim International Gmbh, Genentech, Inc.. Active years: 1996-2026.

USPTO Granted Patents = 41 (Patent Applications = 8)

% Patents Active = 87.8

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 2.5

ph-index = 16

Forward Citations = 977(Granted Patents)

Location History:

Chapel Hill, NC (US) (1996 - 2001)
Birmingham, AL (US) (1999 - 2007)
Saint Louis, MO (US) (2016)
St. Louis, MO (US) (2019 - 2023)

Company Filing History:

30 out of 641

The UAB Research Foundation (The University of Alabama at Birmingham)

patents

4 out of 1,560

Boehringer Ingelheim International Gmbh

The University of North Carolina at Chapel Hill

patents

5. 2 out of 692

Beckman Research Institute, City of Hope

patents

6. 2 out of 962

The University of Chicago

patents

7. 2 out of 1,376

Washington University

patents

8. 1 out of 306

Boehringer Ingelheim Gmbh

The University of Texas System

patents

11. 1 out of 1

Unleash Immuno Oncolytics, Inc.

patent

12. 3 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 1996-2026

Loading Chart...

Areas of Expertise:

Adenoviral Vectors

Virotherapy

Gene Therapy

Immunomodulation

Cancer Treatment

Genetic Induction

Tumor Cell Sensitivity

Nucleic Acid Complexes

Recombinant Adenovirus

Single-Chain Antibodies

Tropic Cell-Based Therapy

Conditionally-Replicative Adenovirus

41 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12584145 - CONJUGATE SYSTEMS AND METHODS OF USE THEREOF (2026-03-24),

2. 11542526 - Oncolytic adenoviral vector and methods of use (2023-01-03),

3. 10709745 - Tropic cell based virotherapy for the treatment of cancer (2020-07-14),

4. 10391183 - Infectivity-enhanced conditionally-replicative adenovirus and uses thereof (2019-08-27),

5. 10238699 - Tropic cell based virotherapy for the treatment of cancer (2019-03-26),

6. 9267153 - Porcine knob xenotype chimeric adenoviral vector for dendritic cell infection (2016-02-23),

7. 7297542 - Adenovirus vector containing a heterologous peptide epitope in the hi loop of the fiber knob (2007-11-20),

8. 7045127 - Human anti-epidermal growth factor receptor single-chain antibodies (2006-05-16),

9. 6955808 - Capsid-modified recombinant adenovirus and methods of use (2005-10-18),

10. 6841540 - Immunomodulation by genetic modification of dendritic cells and B cells (2005-01-11),

11. 6824771 - Infectivity-enhanced conditionally-replicative adenovirus and uses thereof (2004-11-30),

12. 6815200 - Modified adenovirus containing a fiber replacement protein (2004-11-09),

13. 6716823 - Noninvasive genetic immunization, expression products therefrom, and uses thereof (2004-04-06),

14. 6716622 - Tissue-specific self-inactivating gene therapy vector (2004-04-06),

15. 6706693 - Vaccination by topical application of genetic vectors (2004-03-16),

Title: David T Curiel: Innovator in Cancer Research and Therapeutics

Introduction

David T Curiel is a prominent inventor based in Birmingham, Alabama, known for his groundbreaking contributions to cancer research through innovative therapies. With an impressive portfolio consisting of 33 patents, Curiel has made significant strides in the field of oncolytic virotherapy, focusing on the development of novel methods to treat cancer.

Latest Patents

Among his latest inventions is a patent for an oncolytic adenoviral vector and methods of use. This invention involves a conditionally-replicating serotype 5 adenovirus or adenoviral vector that expresses a mutant E1A protein controlled by a promoter responsive to hypoxia and inflammation. The vector also comprises serotype 3 fiber and hexon proteins, presenting a method for inducing cytotoxicity in tumor cells through an innovative composition. Another notable patent is for tropic cell-based virotherapy, where the methods provided include killing tumor cells by using a tropic cell that carries a modified oncolytic virus with tumor selective elements. These advancements illustrate Curiel’s commitment to addressing complex challenges in cancer treatment.

Career Highlights

Curiel's career is marked by his association with the UAB Research Foundation, where he has contributed to several pioneering projects related to therapeutic developments. His work has not only advanced the understanding of cancer therapies but has also opened new avenues for research and development in oncology.

Collaborations

Throughout his career, David T Curiel has collaborated with esteemed professionals in the field, including Donald J Buchsbaum and Murray A Stackhouse. These interactions have fostered a collaborative environment that enhances innovation and amplifies the impact of their research endeavors.

Conclusion

David T Curiel exemplifies the role of an inventor committed to making a difference in the medical field, particularly in cancer treatment. With a strong portfolio of patents and valuable collaborations, he continues to push the boundaries of science and research, paving the way for new therapies that could significantly improve patient outcomes.